Prostatic artery embolization is a minimally invasive treatment procedure used for managing lower urinary tract symptoms caused by benign prostatic hyperplasia (BPH). In this procedure, small gelatin or plastic particles are delivered via a catheter into the blood vessels that supply blood to the prostate gland to restrict the blood flow. Benign prostatic hyperplasia is a common non-cancerous enlargement condition affecting aging men, with rising prevalence globally.

The global prostatic artery embolization market is estimated to be valued at US$ 235 million in 2023 and is expected to exhibit a CAGR of 12% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Dynamics

Rising Prevalence of Benign Prostatic Hyperplasia: Prostatic artery embolization acts as an alternative to Transurethral resection of the prostate (TURP), the current gold standard treatment for BPH. The prevalence of BPH increases with age affecting over 50% of men in their 50s and up to 90% in their 80s. With rising geriatric population worldwide, the number of aging men affected by BPH driven lower urinary tract symptoms is expected to surge thereby driving increased adoption of minimally invasive treatments like prostatic artery embolization.

Market Dynamics:

Prostatic artery embolization leverages the opportunity arising from the growing BPH patient pool to emerge as a popular minimally invasive treatment option. Its advantages over TURP such as shorter hospital stay and recovery time along with comparable symptomatic relief attract more urologists and patients. Rising healthcare expenditure in developing nations enhances accessibility to such novel procedures. However, the need for well-equipped angiography suites and appropriately skilled interventional radiologists poses regional deployment challenges. Ongoing clinical trials aim to expand the evidence base to support PAE’s long-term outcomes.

Segment Analysis

The global prostatic artery embolization market is dominated by the benign prostatic hyperplasia (BPH) sub segment. This segment holds more than 70% share owing to rising cases of non-cancerous enlargement of prostate gland mainly caused by aging. With advanced age, it is common for prostatic arteries to develop benign enlargement leading to urinary problems like incomplete emptying of bladder, frequent urination etc. Prostatic artery embolization offers a minimally invasive treatment option with shorter hospital stay and recovery time compared to traditional surgery methods of prostate removal.

PEST Analysis

Political: Governments across developed nations are increasingly supporting minimally invasive treatments over surgery to curb rising healthcare costs. favorable reimbursement policies are in place for procedures like prostatic artery embolization.
Economic: Rising geriatric population and heavy disease burden of BPH along with greater patient acceptance of image guided therapies is fueling market growth. However, availability of traditional surgery alternatives can impede demand.
Social: Growing awareness among people regarding treatment advances is helping address social stigmas around procedures. Patient support groups are promoting non-surgical options.
Technological: Advancements in embolization microspheres, catheter materials and imaging technologies like CT/Fluoroscopy allow for more accuracy in blocking targeted arteries and monitoring therapy effects. Development of biodegradable embolic agents can enhance safety.

Key Takeaways

The global Prostatic Artery Embolization Market Share is expected to witness high growth at a CAGR of around 12% during the forecast period of 2023 to 2030. The global prostatic artery embolization market is estimated to be valued at US$ 235 million in 2023 and is expected to exhibit a CAGR of 12% over the forecast period 2023 to 2030.

\North America holds the highest market share currently owing to developed healthcare infrastructure, favorable reimbursement policies and higher acceptance of image guided minimally invasive procedures compared to invasive surgeries. Europe is also an established regional market. The Asia Pacific region is projected to demonstrate the fastest growth over the coming years. This can be attributed to rising geriatric population, growing healthcare expenditures, increasing awareness about treatment advancements and greater availability of interventional radiology services. Countries like India, China, Japan and South Korea are likely to significantly contribute to market expansion in Asia Pacific.

Key players related content comprises
Key players operating in the prostatic artery embolization market are Amgen Inc., Samsung Bioepis Co., Ltd., Sandoz International GmbH (Novartis AG), Mylan N.V., Boehringer Ingelheim International GmbH, Pfizer Inc., Fresenius Kabi AG, Coherus BioSciences, Inc., Biogen Inc., AbbVie Inc., Celltrion Inc., Amneal Pharmaceuticals, Inc., Lupin Pharmaceuticals, Inc., Merck & Co., Inc., Viatris Inc. Key players are focusing on new product approvals and launches and geographical expansion strategies to consolidate their market shares.

*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it